Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.58 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.51 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.48 |
| ▸ | DAO | P14920 | 2/20 | 0.48 |
| ▸ | F2 | P00734 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.43 |
| ▸ | NHERF1 | O14745 | 1/20 | 0.43 |
| ▸ | PYGL | P06737 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6824873 | 0.89 | LOXL2 (0.60) | LOXL2SIRT1PCSK9DAOF2 | |
| SCHEMBL6990180 | 0.87 | PCSK9 (0.55) | LOXL2PCSK9DAOF2HCAR2 | |
| SCHEMBL6826452 | 0.85 | LOXL2 (0.64) | LOXL2SIRT1PCSK9DAOF2 | |
| SCHEMBL6990646 | 0.84 | DRD2 (0.49) | LOXL2SIRT1PCSK9DAOF2 | |
| SCHEMBL866136 | 0.84 | LOXL2 (0.72) | LOXL2SIRT1PCSK9DAOSMN1; SMN2 | |
| SCHEMBL8802664 | 0.79 | LOXL2 (0.57) | LOXL2SIRT1PCSK9DAOF2 | |
| SCHEMBL6989299 | 0.79 | LOXL2 (0.57) | LOXL2SIRT1PCSK9DAOF2 | |
| SCHEMBL6826669 | 0.76 | PCSK9 (0.57) | LOXL2SIRT1PCSK9DAOF2 | |
| SCHEMBL12096730 | 0.75 | SIRT1 (0.56) | LOXL2SIRT1DAOF2SMN1; SMN2 | |
| SCHEMBL11174142 | 0.74 | LOXL2 (0.68) | LOXL2SIRT1PCSK9DAOSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040009976-A1 | Hypoglycemic imidazoline compounds | TAKEUCHI KUMIKO (US) | 2004-01-15 | — | — | US | disclosed |
| EP-0924209-B1 | Hypoglycemic imidazoline compounds | LILLY CO ELI (US) | 2003-05-02 | — | — | EP | disclosed |
| EP-1266897-A2 | Hypoglycemic imidazoline compounds | ELI LILLY AND COMPANY (US) | 2002-12-18 | — | — | EP | disclosed |
| US-6410562-B1 | ANTIDIABETIC AGENTS | ELI LILLY AND COMPANY | 2002-06-25 | — | — | US | disclosed |
| WO-1999032482-A1 | HYPOGLYCEMIC IMIDAZOLINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 1999-07-01 | — | — | WO | disclosed |
| EP-0924209-A1 | Hypoglycemic imidazoline compounds | ELI LILLY AND COMPANY (US) | 1999-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009976-A1 | Hypoglycemic imidazoline compounds | GPR119, IAPP, GLP1R | LOXL2 4801/4885SIRT1 103/4885PCSK9 807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.